Products for Research Use Only

Atibuclimab

CAT: 0804-HY-P99008-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99008-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (LPS) -induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury[1][2].
CAS Number
2417175-94-9
Product Name Alternative
IC14
UNSPSC
12352203
Target
Toll-like Receptor (TLR)
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/atibuclimab.html
Purity
99.06
Solubility
H2O
Smiles
[Atibuclimab]
Molecular Weight
(145.5 kDa)
References & Citations
[1]Henderson RD, Agosti JM, McCombe PA, et al. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine (Baltimore) . 2021;100 (42) :e27421. |[2]Verbon A, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol. 2001;166 (5) :3599-3605.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2